Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content

Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies. Sirolimus has low oral bioavailability and exhibits large pharmacokinetic variability. The underlying mechanisms for this variability have not been explored to a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Emoto, C, Fukuda, T, Cox, S, Christians, U, Vinks, A A
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731827/
https://ncbi.nlm.nih.gov/pubmed/23884207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2013.33
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares